Abstract:OBJECTIVE Glucocorticoid (GC) has occupied a central role in the treatment of acute lymphoblastic leukemia due to its ability to induce apoptosis in neoplastic lymphoid cells. Glucocorticoid resistance is present among 20% initial acute lymphoblastic leukemia, even 80% refractory acute lymphoblastic leukemia. Glucocorticoid resistance has been an important determinant of clinical outcome. Glucocorticoid depends on glucocorticoid receptor (GR) to induce apoptosis. Glucocorticoid receptor, a number of nuclear hormone receptor superfamily, is mediated by many signal transduction systems. The mitogen-activated protein kinases (MAPK) superfamily of serine/threonine kinases has emerged as an important component of cellular signal transduction. Four MAP kinase families, ERK, p38 MAP kinase, JNK, and ERK5, have been well characterized. p38 MAPK usually plays a role in regulating apoptosis, cell cycle arrest and cytokines production, et al. In steroid resistance patients, IL-2 combined with IL-4 can decrease glucocorticoid receptor ligand-binding affinity via p38MAPK. In human alveolar epithelial A549 cells, dexamethasone could inhibit the activation of p38MAPK. It is unclear that the effect of p38MAPK on glucocorticoid receptor function induced by dexamethasone in CEM cells. This study aimed to investigate effect of p38 mitogen-activated protein kinase on glucocorticoid receptor function induced by dexamethasone in CEM cells. METHODS Cell viability was determined by trypan blue dye exclusion. Apoptosis was evaluated by morphology and flow cytometry. Glucocorticoid receptor protein and p-p38MAPK protein were analyzed by Western Blot. RESULTS When treatment with SB203580 and dexamethasone for 24 h to 72 h, the survival percentage was increased from 62.3%, 35.5% and 11.6% to 82.8%, 54.7% and 48.1%, respectively (P < 0.01). Co-treatment with SB203580 and dexamethasone resulted in the decrease of apoptotic percentage from 26.2% to 7.1% for 36 h (P < 0.01). p38 MAPK activation was apparent at 15 min, peaked at 1 h after dexamethasone treatment, and was sustained for 6 h. The phosphorylation was still observed at 48 h. Treatment with dexamethasone at 5 micromol/L for 12, 24, 36 and 48 h resulted in increase of GR(alpha) protein to 117%, 121%, 122% and 125% respectively. Unbinding to dexamethasone, GR(alpha) is in the cytoplasm. Nuclear-to-cytoplasmic ratio of GR(alpha) is 0.27. Treatment with dexamethasone at the same concentration and time resulted in the nuclear-to-cytoplasmic ratio increase to 0.48, 0.59, 0.95, 2.16 and 4.08 respectively. Combined treatment with SB203580 and dexamethasone resulted in the nuclear-to-cytoplasmic ratio decrease from 4.08 to 0.43 for 48 h (P < 0.05). The total GR(alpha) protein was unaffected. CONCLUSIONS Expression of GR(alpha) protein is upregulated and translocated into nucleus. p38MAPK enhances GR(alpha) protein translocation into nucleus.

Dexamethasone Enhances Programmed Cell Death 1 (PD-1) Expression During T Cell Activation: an Insight into the Optimum Application of Glucocorticoids in Anti-Cancer Therapy

Dexamethasone inhibits the antigen presentation of dendritic cells in MHC class II pathway.

Dexamethasone inhibits pancreatic tumor growth in preclinical models: Involvement of activating glucocorticoid receptor

Corticosteroid Co-Treatment Induces Resistance to Chemotherapy in Surgical Resections, Xenografts and Established Cell Lines of Pancreatic Cancer

Dexamethasone inhibits the proliferation of tumor cells

High-Dose Dexamethasone Manipulates the Tumor Microenvironment and Internal Metabolic Pathways in Anti-Tumor Progression

Dexamethasone suppresses immune evasion by inducing GR/STAT3 mediated downregulation of PD-L1 and IDO1 pathways

Revisit the Inhibitory Effects of Glucocorticoids on Immunocytes

Corticosteroids Induce Chemotherapy Resistance in the Majority of Tumour Cells from Bone, Brain, Breast, Cervix, Melanoma and Neuroblastoma.

Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer

Dexamethasone enhances cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells

A glucocorticoid amplifies IL-2-induced selective expansion of CD4(+)CD25(+)FOXP3(+) regulatory T cells in vivo and suppresses graft-versus-host disease after allogeneic lymphocyte transplantation.

Glucocorticoid Reduces Pemetrexed Sensitivity by Mediating Senescence-Associated Secretory Phenotype in Bcl-2 Dependent Manner in Non-Small-Cell Lung Cancer

Dexamethasone Disrupts Cytoskeleton Organization and Migration of T47D Human Breast Cancer Cells by Modulating the AKT/mTOR/RhoA Pathway.

[P38 Mitogen-Activated Protein Kinase Mediates Glucocorticoid Receptor Function Induced by Dexamethasone in Acute Lymphoblastic Leukemia Cells].

Dexamethasone Suppresses DU145 Cell Proliferation and Cell Cycle Through Inhibition of the Extracellular Signal-Regulated Kinase 1/2 Pathway and Cyclin D1 Expression

Dexamethasone As A Chemosensitizer for Breast Cancer Chemotherapy: Potentiation of the Antitumor Activity of Adriamycin, Modulation of Cytokine Expression, and Pharmacokinetics

Dexamethasone Potentiates Myeloid-Derived Suppressor Cell Function in Prolonging Allograft Survival Through Nitric Oxide

Impact of Prophylactic Dexamethasone on the Efficacy of Immune Checkpoint Inhibitors Plus Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer

Function of Regulatory T-Cells Improved by Dexamethasone in Graves' Disease

An in Vitro and in Vivo Study of the Effect of Dexamethasone on Immunoinhibitory Function of Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells.